GW Pharmaceuticals PLC- (NASDAQ:GWPH) – Investment analysts at Piper Jaffray Companies increased their FY2019 EPS estimates for shares of GW Pharmaceuticals PLC- in a report issued on Tuesday, November 5th. Piper Jaffray Companies analyst D. Brill now anticipates that the biopharmaceutical company will earn ($3.44) per share for the year, up from their previous forecast of ($4.28). Piper Jaffray Companies also issued estimates for GW Pharmaceuticals PLC-‘s Q4 2019 earnings at ($0.60) EPS, Q1 2020 earnings at ($0.36) EPS, Q2 2020 earnings at $0.12 EPS, Q3 2020 earnings at $0.48 EPS, Q4 2020 earnings at $0.96 EPS, FY2020 earnings at $1.32 EPS, FY2021 earnings at $7.92 EPS and FY2022 earnings at $12.96 EPS.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($1.74) by $0.96. The firm had revenue of $72.04 million during the quarter, compared to analysts’ expectations of $37.28 million. GW Pharmaceuticals PLC- had a negative return on equity of 23.44% and a negative net margin of 26.80%. The business’s quarterly revenue was up 2096.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.25) earnings per share.
Other research analysts also recently issued reports about the company. HC Wainwright reaffirmed a “buy” rating on shares of GW Pharmaceuticals PLC- in a report on Friday. Oppenheimer decreased their price objective on GW Pharmaceuticals PLC- to $222.00 and set an “outperform” rating for the company in a report on Wednesday. Bank of America reissued a “buy” rating and set a $218.00 price objective on shares of GW Pharmaceuticals PLC- in a report on Wednesday, September 25th. Zacks Investment Research lowered GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a report on Friday, October 18th. Finally, ValuEngine raised GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a report on Wednesday, September 4th. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $203.83.
GWPH stock traded up $1.40 during midday trading on Friday, reaching $110.44. 13,914 shares of the stock were exchanged, compared to its average volume of 533,203. The stock has a market capitalization of $4.16 billion, a PE ratio of -10.40 and a beta of 2.28. GW Pharmaceuticals PLC- has a 52 week low of $90.14 and a 52 week high of $196.00. The company has a debt-to-equity ratio of 0.03, a current ratio of 8.31 and a quick ratio of 7.59. The company has a fifty day moving average price of $123.21 and a 200 day moving average price of $154.46.
In other news, insider Douglas B. Snyder sold 5,424 shares of the stock in a transaction on Monday, August 19th. The shares were sold at an average price of $13.04, for a total value of $70,728.96. Following the sale, the insider now owns 73,740 shares in the company, valued at $961,569.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Douglas B. Snyder sold 3,756 shares of the stock in a transaction on Monday, August 12th. The stock was sold at an average price of $13.88, for a total transaction of $52,133.28. Following the completion of the sale, the insider now owns 79,164 shares in the company, valued at approximately $1,098,796.32. The disclosure for this sale can be found here. 3.60% of the stock is owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in the company. Kavar Capital Partners LLC bought a new stake in shares of GW Pharmaceuticals PLC- during the second quarter valued at about $26,000. Signaturefd LLC raised its stake in GW Pharmaceuticals PLC- by 192.5% during the 3rd quarter. Signaturefd LLC now owns 234 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 154 shares during the period. Prestige Wealth Management Group LLC acquired a new position in GW Pharmaceuticals PLC- during the 2nd quarter worth approximately $28,000. Pathstone Family Office LLC acquired a new position in GW Pharmaceuticals PLC- during the 2nd quarter worth approximately $29,000. Finally, Valeo Financial Advisors LLC raised its stake in GW Pharmaceuticals PLC- by 322.6% during the 3rd quarter. Valeo Financial Advisors LLC now owns 262 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 200 shares during the period. Hedge funds and other institutional investors own 82.89% of the company’s stock.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.